The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
CD138 (Syndecan-1), a Plasma Cell Marker: Immunohistochemical Profile in Hematopoietic and Nonhematopoietic Neoplasms
Abstract
We evaluated the immunohistochemical profile and specificity of CD138 reactivity in 238 specimens from hematopoietic and nonhematopoietic neoplasms. In 91 bone marrow biopsies, CD138 reactivity was observed for nonneoplastic plasma cells, neoplastic plasma cells in multiple myeloma cases (43/43), and the plasmacytic component in lymphoplasmacytic lymphoma cases (4/4). Stromal reactivity was noted in 7 multiple myeloma cases. Of 9 bone marrow specimens involved by metastatic carcinoma, tumor cells were CD138+ in 5 cases; stromal reactivity was noted in 7 cases. Studies of 76 nodal and extranodal lymphomas (B-cell, 49; T-cell, 8; Hodgkin lymphoma, 19), 1 Langerhans cell histiocytosis, and 14 nonneoplastic lymph nodes revealed CD138 reactivity only for nonneoplastic plasma cells, the neoplastic cells of 2 large B-cell lymphomas (immunoblastic type, plasmacytoid features), and the clonal plasmacytic component of 3 of 3 extranodal and 1 nodal marginal zone lymphoma. Evaluation of 56 epithelial and nonepithelial tumors revealed CD138 positivity for neoplastic cells of carcinomas of various types (30/33), frequently with associated stromal reactivity, and for neoplasms of mesenchymal, melanocytic, and other tumor types (12/23). Within the hematopoietic system, CD138 is an excellent marker of plasmacytic differentiation. Based on its broad staining profile, CD138 reactivity for neoplastic cells is not a definitive marker for plasmacytic derivation, unless a hematolymphoid origin has been established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of the Syndecans: A Family of Transmembrane Heparan Sulfate Proteoglycans
Bernfield, M., Kokenyesi, R., Kato, M., Hinkes, M. T., Spring, J., Gallo, R. L., & Lose, E. J. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.002053 · Cited by 1,097
A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1
Wijdenes, J., Vooijs, W. C., Clément, C., Post, J., Morard, F., Vita, N., Laurent, P., Sun, R., Klein, B., & Dore, J. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-1811.x · Cited by 340
Hayashi, K., Hayashi, M., Jalkanen, M., Firestone, J. H., Trelstad, R. L., & Bernfield, M. (1987) · Journal of Histochemistry & Cytochemistry · doi:10.1177/35.10.2957423 · Cited by 247
Induced expression of syndecan in healing wounds.
Elenius, K., Vainio, S., Laato, M., Salmivirta, M., Thesleff, I., & Jalkanen, M. (1991) · The Journal of cell biology · doi:10.1083/jcb.114.3.585 · Cited by 242
Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen
Ridley, R., Xiao, H., Hata, H., Woodliff, J., Epstein, J., & Sanderson, R. (1993) · Blood · doi:10.1182/blood.v81.3.767.767 · Cited by 226
Kurtin, P. J., & Pinkus, G. S. (1985) · Human Pathology · doi:10.1016/s0046-8177(85)80229-x · Cited by 212
Self-citationSequence of human syndecan indicates a novel gene family of integral membrane proteoglycans.
Mali, M., Jaakkola, P., Arvilommi, A. M., & Jalkanen, M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39232-4 · Cited by 176
Inki, P., Joensuu, H., Grénman, R., Klemi, P., & Jalkanen, M. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.300 · Cited by 166
Function of the syndecans - a family of cell surface proteoglycans
Elenius, K., & Jalkanen, M. (1994) · Journal of Cell Science · doi:10.1242/jcs.107.11.2975 · Cited by 147
Binding of human syndecan to extracellular matrix proteins.
Elenius, K., Salmivirta, M., Inki, P., Mali, M., & Jalkanen, M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)38239-5 · Cited by 136
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B. P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 559
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Tafe, L. J., Garg, K., Chew, I., Tornos, C., & Soslow, R. A. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.41 · Cited by 261
Beauvais, D. M., Jung, O., Yang, Y., Sanderson, R. D., & Rapraeger, A. C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0232 · Cited by 70
Metadata
- Authors
- O’Connell, F. P., Pinkus, J. L., & Pinkus, G. S.
- Venue
- American Journal of Clinical Pathology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-02
- Volume
- 121
- Issue
- 2
- Pages
- 254-263
- ISSN
- 0002-9173 (ISSN-L)
- 1943-7722
- OpenAlex
- W2409645736
- Cited by
- 263
- References
- 19
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD138 (Syndecan-1), a Plasma Cell Marker: Immunohistochemical Profile in Hematopoietic and Nonhematopoietic Neoplasms. https://app.cochat.ai/papers/10.1309/617dwb5gnfwxhw4l
- The paper
- O’Connell, F. P., Pinkus, J. L., & Pinkus, G. S. (2004). CD138 (Syndecan-1), a Plasma Cell Marker: Immunohistochemical Profile in Hematopoietic and Nonhematopoietic Neoplasms. American Journal of Clinical Pathology. https://doi.org/10.1309/617dwb5gnfwxhw4l
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
